365 related articles for article (PubMed ID: 12962513)
1. Aldosterone receptor antagonists for hypertension: what do they offer?
Liew D; Krum H
Drugs; 2003; 63(19):1963-72. PubMed ID: 12962513
[TBL] [Abstract][Full Text] [Related]
2. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
3. Eplerenone: a selective aldosterone receptor antagonist (SARA).
Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
Takeda Y
Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
6. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
Davis KL; Nappi JM
Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone antagonists in hypertension and heart failure.
Mantero F; Lucarelli G
Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone: a selective aldosterone blocker.
Stier CT
Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
[TBL] [Abstract][Full Text] [Related]
9. The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure.
Hameedi A; Chadow HL
Curr Hypertens Rep; 2000 Aug; 2(4):378-83. PubMed ID: 10981173
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
George J; Struthers AD
Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
[TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid receptor antagonists and hypertension: is there a rationale?
Gumieniak O; Williams GH
Curr Hypertens Rep; 2004 Aug; 6(4):279-87. PubMed ID: 15257862
[TBL] [Abstract][Full Text] [Related]
12. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
McMahon EG
Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
Adams KF
Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of aldosterone blockade.
Weber MA
Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
[TBL] [Abstract][Full Text] [Related]
17. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone target organ protection by eplerenone.
Rudolph AE; Rocha R; McMahon EG
Mol Cell Endocrinol; 2004 Mar; 217(1-2):229-38. PubMed ID: 15134822
[TBL] [Abstract][Full Text] [Related]
19. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
Brennan BJ; Martin NE
J Am Pharm Assoc (2003); 2004; 44(5):604-10; quiz 610-1. PubMed ID: 15496047
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
